Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Open-Label, Dose Titration, Safety and Efficacy Study of FG-4592 for the Correction of Anemia in Newly Initiated Dialysis Patients Not on Erythropoiesis-Stimulating Agent Treatment
Brief Summary: The purpose of this study is to evaluate efficacy and safety of roxadustat in the correction of anemia in participants with end-stage renal disease who recently started dialysis.


Options:
A: Arm Label: Daprodustat receivers; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat (GSK1278863), Drug: Iron therapy | Arm Label: Placebo receivers; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Iron therapy | Intervention Type: DRUG; Name: Daprodustat (GSK1278863); Assigned to Arm(s): Daprodustat receivers | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo receivers | Intervention Type: DRUG; Name: Iron therapy; Assigned to Arm(s): Daprodustat receivers, Placebo receivers
B: Arm Label: Molidustat (BAY85-3934); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934) | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Molidustat (BAY85-3934); Assigned to Arm(s): Molidustat (BAY85-3934) | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
C: Arm Label: Arm A + E (Participants on HD): Roxadustat Only, No Iron; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat, Drug: Oral Iron | Arm Label: Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat, Drug: IV Iron | Arm Label: Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat, Drug: Oral Iron | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Arm A + E (Participants on HD): Roxadustat Only, No Iron, Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg, Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg, Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Intervention Type: DRUG; Name: Oral Iron; Assigned to Arm(s): Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg, Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Intervention Type: DRUG; Name: IV Iron; Assigned to Arm(s): Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg
D: Arm Label: Molidustat (BAY85-3934); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934) | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Molidustat (BAY85-3934); Assigned to Arm(s): Molidustat (BAY85-3934) | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa

Answer: C